Posted by Michael Wonder on 09 Jul 2020
Assembly Biosciences announces FDA fast track designation granted to ABI-H2158 for the treatment of chronic hepatitis B virus infection
9 July 2020 - Assembly Biosciences today announced that the U.S. FDA has granted fast track designation to ABI-H2158 (2158) for the treatment of patients with chronic HBV infection.
2158 is Assembly’s second-generation core inhibitor, which is being evaluated in an ongoing global Phase 2 trial.
